Alzamend Neuro Inc (ALZN) concluded trading on Thursday at a closing price of $5.44, with 77.61 million shares of worth about $422.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.86% during that period and on May 29, 2025 the price saw a gain of about 63.86%. Currently the company’s common shares owned by public are about 0.80M shares, out of which, 0.77M shares are available for trading.
Stock saw a price change of 54.55% in past 5 days and over the past one month there was a price change of -9.05%. Year-to-date (YTD), ALZN shares are showing a performance of -47.89% which decreased to -89.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.06 but also hit the highest price of $135.54 during that period. The average intraday trading volume for Alzamend Neuro Inc shares is 131.06K. The stock is currently trading 20.98% above its 20-day simple moving average (SMA20), while that difference is down -15.11% for SMA50 and it goes to -53.60% lower than SMA200.
Alzamend Neuro Inc (NASDAQ: ALZN) currently have 0.80M outstanding shares and institutions hold larger chunk of about 0.88% of that.
The stock has a current market capitalization of $4.36M and its 3Y-monthly beta is at -0.31. It has posted earnings per share of -$27.58 in the same period. It has Quick Ratio of 5.44 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALZN, volatility over the week remained 26.09% while standing at 14.62% over the month.
Stock’s fiscal year EPS is expected to rise by 89.05% while it is estimated to increase by 24.22% in next year. EPS is likely to grow at an annualized rate of 61.95% for next 5-years, compared to annual growth of -11.45% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ascendiant Capital Markets on October 01, 2021 offering a Buy rating for the stock and assigned a target price of $8 to it.
